GSK to buy rare cancer drug developer IDRx for up to £1bn
GSK will pay $1bn upfront to acquire the Massachussetts-based company IDRx is developing a treatment for gastrointestinal stromal tumours (GIST)By HARRY WISE Updated: 04:21 EST, 13 January 2025 <!--
!-->>-->!-->>!-->>!-->-->!-->>!-->>!-->>!-->>-->!-->!-->…